Most Recent

A patent dispute over CRISPR highlights the need for scientists to agree on IP ownership early.

0 Comments

image: Opinion: Pay-to-Play Publishing

Opinion: Pay-to-Play Publishing

By | September 3, 2015

Online scientific journals are sacrificing the quality of research articles to make a buck.

2 Comments

image: Opinion: How Postdocs Can Participate

Opinion: How Postdocs Can Participate

By | September 18, 2014

Graduate students and postdoctoral researchers should be taking part in discussions on the future of biomedical research.

6 Comments

image: Opinion: #IceBucketChallenge, Investing Well

Opinion: #IceBucketChallenge, Investing Well

By | September 10, 2014

Hundreds of thousands participated in the ALS campaign that went viral, but how are they supposed to decide where to donate?

3 Comments

image: Opinion: The Pitfalls of Uncertainty

Opinion: The Pitfalls of Uncertainty

By | April 14, 2014

How to successfully inform policy when scientific evidence is not plainly evident.

2 Comments

image: Opinion: Of Mice and Men

Opinion: Of Mice and Men

By | December 3, 2013

Researchers scramble to put mouse cancer models on solid footing.

1 Comment

image: Opinion: Researching the Researchers

Opinion: Researching the Researchers

By | November 25, 2013

The biomedical research community is due for some self-reflection.

9 Comments

image: Opinion: Who We Work For

Opinion: Who We Work For

By | November 5, 2013

On winning hearts, minds, and votes for science

1 Comment

image: Opinion: Research, Restricted

Opinion: Research, Restricted

By | July 8, 2013

Are the international drug laws the worst impediment to scientific inquiry since the Catholic Church banned the telescope?

4 Comments

image: Opinion: The Payoff of Big Science

Opinion: The Payoff of Big Science

By | June 3, 2013

Was the Human Genome Project the key to a gold mine?

3 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech